Pediatr Nephrol (2008) 23:527–535 and its role in orchestrating cellular protein turnover (http:// nobelprize.org/chemistry/laureates/2004/). Acknowledgements Supported by NIH grants R01 DK37175, P50 DK64233 and T32 DK62706. Reference 1. Qureshi AR, Alvestrand A, Danielsson A, Divino-Filho JC, Gutierrez A, Lindholm B, Bergstrom J (1998) Factors predicting malnutrition in hemodialysis patients: A cross-sectional study. Kidney Int 53:773–782 2. Kopple JD (2001) National Kidney Foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis 37:S66–S70 3. Mitch WE (2002) Malnutrition: a frequent misdiagnosis for hemodialysis patients. J Clin Invest 110:437–439 4. Kaysen GA, Dubin JA, Muller H-G, Rosales L, Levin NW, Mitch WE (2004) Inflammation and reduced albumin synthesis associ- ated with stable decline in serum albumin in hemodialysis patients. Kidney Int 65:1408–1415 5. Bailey JL, Wang X, England BK, Price SR, Ding X, Mitch WE (1996) The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent, ubiquitin-proteasome pathway. J Clin Invest 97:1447–1453 6. Price SR, Bailey JL, Wang X, Jurkovitz C, England BK, Ding X, Phillips LS, Mitch WE (1996) Muscle wasting in insulinopenic rats results from activation of the ATP-dependent, ubiquitin- proteasome pathway by a mechanism including gene transcrip- tion. J Clin Invest 98:1703–1708 7. Song Y-H, Li Y, Du J, Mitch WE, Rosenthal N, Delafontaine P (2005) Muscle-specific expression of insulin-like growth factor-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest 115:451–458 8. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T (1999) Strong association between malnutrition, inflammation and atherosclerosis in chronic kidney failure. Kidney Int 55:1899–1911 9. Lim VS, Kopple JD (2000) Protein metabolism in patients with chronic renal failure: Role of uremia and dialysis. Kidney Int 58:1–10 10. Mitch WE, Goldberg AL (1996) Mechanisms of muscle wasting: The role of the ubiquitin-proteasome system. N Engl J Med 335:1897–1905 11. Pickering WP, Price SR, Bircher G, Marinovic AC, Mitch WE, Walls J (2002) Nutrition in CAPD: Serum bicarbonate and the ubiquitin-proteasome system in muscle. Kidney Int 61:1286– 1292 12. Glickman MH, Ciechanover A (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82:373–428 13. Pickart CM (2004) Back to the future with ubiquitin. Cell 116:181–190 14. Baumeister W, Walz J, Zuhl F, Seemuller E (1998) The proteasome: paradigm of a self-compartmentalizing protease. Cell 92:367–380 15. Lecker SH, Goldberg AL, Mitch WE (2006) Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol 17:1807–1819 16. Muratani M, Tansey WP (2003) How the ubiquitin-proteasome system controls transcription. Nat Rev Mol Cell Biol 4:192–201 533 17. Lipford JR, Smith GT, Chi Y, Deshaies RJ (2005) A putative stimulatory role for activator turnover in gene expression. Nature 438:113–116 18. Karin M, Ben-Neriah Y (2000) Phosphorylation meets ubiquiti- nation: the control of NF-[kappa]B activity. Annu Rev Immunol 18:621–663 19. Kisselev AF, Akopian TN, Woo KM, Goldberg AL (1999) The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes. Implications for understanding the degradative mechanism and antigen presentation. J Biol Chem 274:3363–3371 20. Adams J (2004) The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4:349–360 21. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T (1994) The ubiquitin-proteasome pathway is required for processing the NF- kB1 precursor protein and the activation of NF-kB. Cell 78: 773–785 22. Kisselev AF, Goldberg AL (2001) Proteasome inhibitors: from research tools to drug candidates. Chem Biol 8:739–758 23. Jensen TJ, Loo MA, Pind S, Williams DB, Goldberg AL, Riordan JR (1995) Multiple proteolytic systems, including the proteasome contribute CFTR processing. Cell 83:129–135 24. Meusser B, Hirsch C, Jarosch E, Sommer T (2005) ERAD: the long road to destruction. Nat Cell Biol 7:766–772 25. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, Goldberg AL (1994) Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class 1 molecules. Cell 78:761–771 26. Hicke L, Dunn R (2003) Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins. Annu Rev Cell Dev Biol 19:141–172 27. Sigismund S, Polo S, Di Fiore PP (2004) Signaling through monoubiquitination. Curr Top Microbiol Immunol 286:149–185 28. Lecker SH, Jagoe RT, Gomes M, Baracos V, Bailey JL, Price SR, Mitch WE, Goldberg AL (2004) Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 18:39–51 29. Mansoor O, Beaufrere Y, Boirie Y, Ralliere C, Taillandier D, Aurousseau E, Schoeffler P, Arnal M, Attaix D (1996) Increased mRNA levels for components of the lysosomal, Ca++-activated and ATP-ubiquitin-dependent proteolytic pathways in skeletal muscle from head trauma patients. Proc Natl Acad Sci USA 93:2714–2718 30. Tiao G, Hobler S, Wang JJ, Meyer TA, Luchette FA, Fischer JE, Hasselgren P-O (1997) Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle. J Clin Invest 99:163–168 31. Williams AB, Sun X, Fischer JE, Hasselgren P-O (1999) The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery 126:744–749 32. Mitch WE, Bailey JL, Wang X, Jurkovitz C, Newby D, Price SR (1999) Evaluation of signals activating ubiquitin-proteasome proteolysis in a model of muscle wasting. Am J Physiol 276: C1132–C1138 33. Tawa NE, Odessey R, Goldberg AL (1997) Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles. J Clin Invest 100:197–203 34. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clark BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuel DM, DeChiara TM, Stitt TN, Yancopoulos GD, Glass DJ (2001) Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294:1704–1708 35. Lee SW, Dai G, Hu Z, Wang X, Du J, Mitch WE (2004) Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylino- sitol 3 kinase. J Am Soc Nephrol 15:1537–1545